-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Semax 10mg is a synthetic research peptide studied in relation to ACTH fragment analogue research, neuropeptide signalling, neurotrophic pathway models, BDNF-related gene expression research and broader neuroscience research contexts.
Semax is commonly described as an ACTH fragment analogue. PubChem lists Semax under the name ACTH 4-7, Pro-Gly-Pro, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and molecular formula C37H51N9O10S.
This product is supplied for laboratory research use only. It is not a medicine, supplement, nootropic product, cognitive enhancer, focus product, mood product, stroke treatment, neuroprotective treatment or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Semax |
| Common research names | ACTH 4-7, Pro-Gly-Pro; MEHFPGP; ACTH fragment analogue |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Neuropeptide Research / Cognitive Pathway Research |
| Common research interest | ACTH fragment research, BDNF-related pathways, neurotrophic signalling and gene expression models |
| Peptide type | Synthetic heptapeptide |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, cognitive use, nootropic use or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Semax | Synthetic neuropeptide research peptide | Studied in relation to ACTH fragment and neurotrophic pathway research |
| ACTH 4-7 fragment | Adrenocorticotropic hormone fragment context | Forms the N-terminal research basis of the Semax peptide sequence |
| Pro-Gly-Pro tail | Stabilising tripeptide extension | Commonly discussed in relation to peptide stability research |
| Heptapeptide structure | Seven-amino-acid peptide | Sequence commonly listed as Met-Glu-His-Phe-Pro-Gly-Pro |
| Molecular formula | C37H51N9O10S | Listed in PubChem for Semax |
| Molecular weight | Approximately 813.9 g/mol | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
PubChem lists Semax with the molecular formula C37H51N9O10S, molecular weight of approximately 813.9 g/mol and the sequence H-Met-Glu-His-Phe-Pro-Gly-Pro-OH. Product identity, sequence, purity, salt form and batch information should always be confirmed through supplier documentation and the Certificate of Analysis.
Semax is studied as a synthetic ACTH fragment analogue. In research settings, it is commonly examined for its relationship with neurotrophic signalling, gene expression, stress-response models, neuroplasticity research and cognitive pathway models.
Research literature describes Semax as a peptide made from the ACTH 4-7 fragment with a C-terminal Pro-Gly-Pro tripeptide extension. This structure is commonly discussed in relation to improved metabolic stability compared with the native ACTH fragment.
Semax has also been studied in relation to neurotrophin-related gene expression. Research articles discuss Semax and Pro-Gly-Pro in relation to BDNF, NGF and TrkB expression in rat brain research models.
This should be understood as laboratory and preclinical research context only. It should not be used as a claim that a research-use Semax 10mg vial is approved, safe or effective for cognition, focus, mood, anxiety, stroke, brain injury, neuroprotection or human performance.
| Research Area | Semax |
| Main research category | Neuropeptide research |
| Parent pathway context | ACTH fragment analogue research |
| Peptide length | Heptapeptide |
| Common sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Common pathway interest | Neurotrophic signalling, gene expression and neuropeptide pathway research |
| Neurotrophin interest | BDNF, NGF and TrkB-related research models |
| Behavioural research interest | Cognitive pathway, stress-response and neuroplasticity models |
| Evidence limitation | Mostly laboratory, preclinical and limited regional research contexts |
| Product limitation | Research use only, not approved for human use |
| Feature | Semax | Selank |
| Research class | ACTH fragment analogue neuropeptide | Tuftsin analogue neuropeptide |
| Common research focus | Neurotrophic, BDNF-related, cognitive pathway and gene expression research | Stress-response, GABAergic and neuroimmune pathway research |
| Peptide type | Synthetic heptapeptide | Synthetic heptapeptide |
| Common SEO risk | Being marketed as a nootropic, focus or brain peptide | Being marketed as an anxiety, mood or sleep peptide |
| Safer positioning | ACTH fragment research peptide | Tuftsin analogue research peptide |
| Human-use claim | Not appropriate for research-use products | Not appropriate for research-use products |
| Feature | Semax | DSIP |
| Research class | ACTH fragment analogue neuropeptide | Delta sleep-inducing peptide |
| Main research interest | Neurotrophic signalling, gene expression and cognitive pathway research | Sleep architecture, circadian and neuropeptide pathway research |
| Common online claim risk | Focus, nootropic, brain support and cognition | Sleep, relaxation and recovery |
| Safer positioning | ACTH fragment neuropeptide research | Neuropeptide sleep-architecture research |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | Semax | SS-31 |
| Research class | ACTH fragment analogue neuropeptide | Mitochondria-targeted tetrapeptide |
| Main research interest | Neurotrophic and gene expression pathway research | Cardiolipin and inner mitochondrial membrane research |
| Common pathway focus | BDNF, NGF, TrkB and neuropeptide signalling | Mitochondrial membrane, oxidative stress and cardiolipin research |
| Product category | Cognitive pathway research peptide | Mitochondrial research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Common Online Claim | Safer Research-Use Wording |
| Focus | Studied in cognitive pathway and neuropeptide research models |
| Memory support | Better framed as neurotrophic and gene expression research |
| Nootropic | Not an approved or appropriate product claim |
| Brain protection | Better framed as neuroprotection-related preclinical research models |
| Stroke recovery | Not an approved or appropriate product claim for research vials |
| Mood support | Not an approved or appropriate product claim |
| Anxiety support | Not an approved or appropriate product claim |
| Cognitive enhancement | Better framed as cognitive pathway research, not a human benefit claim |
Semax 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for focus, memory, cognition, mood, anxiety, stress relief, stroke recovery, brain injury, neuroprotection, ADHD, nootropic use, sleep, anti-ageing, performance enhancement or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Semax 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Semax 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Semax peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Semax 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Sequence confirmation | Confirmed Semax sequence from CoA or supplier documentation |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
Because Semax is commonly discussed online in relation to cognition, memory, focus, mood and neuroprotection, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, nootropic use or neurological treatment.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide sequence | Helps verify product identity |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a nootropic | Creates human-use and compliance risk |
| Never make focus or memory claims | Not an approved or appropriate product claim |
| Never make stroke or brain injury treatment claims | Not suitable for a research-use product page |
| Never make mood, anxiety or ADHD claims | Not an approved or appropriate product claim |
| Never describe it as cognitive enhancement | Misleading and not appropriate for research-use material |
| Never imply neuroprotective treatment | Research context is not a product-use claim |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Semax is a synthetic research peptide commonly described as an ACTH fragment analogue. It is studied in relation to neuropeptide signalling, neurotrophic pathway research, gene expression models and cognitive pathway research.
Yes. Semax is commonly described as a synthetic heptapeptide, meaning it contains seven amino acids. PubChem lists the Semax sequence as Met-Glu-His-Phe-Pro-Gly-Pro.
Semax is commonly studied in relation to ACTH fragment biology, neurotrophic signalling, BDNF-related gene expression, NGF-related gene expression and neuropeptide pathway research.
This research product is not approved or supplied for focus, memory, cognitive enhancement, nootropic use, mood support, stroke recovery, anxiety, sleep or human administration. It should be described only as a laboratory research product.
No. Semax is commonly discussed as an ACTH fragment analogue, while Selank is commonly discussed as a tuftsin analogue. They are different neuropeptide research products with different research positioning.
No. Semax is usually positioned around ACTH fragment, neurotrophic and cognitive pathway research. DSIP is usually positioned around delta sleep-inducing peptide and sleep-architecture research.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, sequence, salt form and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Semax compound profile | Useful background on Semax identity, sequence, molecular formula and molecular weight. |
| Semax and neurotrophin transcription research | Useful background on Semax, Pro-Gly-Pro, BDNF, NGF and TrkB-related gene expression research. |
| Semax ACTH fragment structure research | Useful background on Semax as an ACTH fragment analogue with a Pro-Gly-Pro extension. |
Research Use Only: Semax 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use, focus, memory, cognition, nootropic use, mood support, anxiety, stress relief, stroke recovery, neuroprotection, brain injury, ADHD, sleep, anti-ageing, body enhancement or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation and qualified laboratory protocols.
